2.15

4.87% -0.11

Ovid Therapeutics Inc (OVID)

Overview News Price History Option Chain Financials Discussions Forecast

Ovid Therapeutics Inc stock is traded at $2.15, with a volume of 1.32M. It is down -4.87% in the last 24 hours and down -19.78% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Previous Close:

$2.26

Open:

$2.26

24h Volume:

1.32M

Relative Volume:

0.96

Market Cap:

$419.89M

Revenue:

$7.12M

Net Income/Loss:

$-24.17M

P/E Ratio:

-8.8332

EPS:

-0.2434

Net Cash Flow:

$-41.95M

1W Performance:

-12.60%

1M Performance:

-19.78%

6M Performance:

-23.21%

1Y Performance:

+36.94%

1-Day Range:

$2.11

$2.30

1-Week Range:

$2.09

$2.4933

52-Week Range:

$1.18

$3.105

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name

Ovid Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

212-776-4381

Address

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Employee

Twitter

@OvidRx

Next Earnings Date

2026-11-11

Latest SEC Filings

OVID's Discussions on Twitter

Compare OVID vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OVID Ovid Therapeutics Inc	2.15	419.89M	7.12M	-24.17M	-41.95M	-0.2434
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-15-26	Initiated	Wolfe Research	Outperform
Oct-09-26	Initiated	Cantor Fitzgerald	Overweight
Oct-06-26	Initiated	Guggenheim	Buy
Dec-11-25	Initiated	Roth Capital	Buy
Nov-17-25	Initiated	Leerink Partners	Outperform
Oct-09-25	Initiated	Oppenheimer	Outperform
Aug-08-25	Resumed	B. Riley Securities	Buy
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy
Apr-29-24	Initiated	H.C. Wainwright	Buy
Apr-05-24	Initiated	Wedbush	Outperform
Dec-21-23	Initiated	BTIG Research	Buy
Oct-13-23	Initiated	Oppenheimer	Outperform
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-19	Initiated	RBC Capital Mkts	Outperform
Apr-20-18	Initiated	Ladenburg Thalmann	Buy

View All

Ovid Therapeutics Inc Stock (OVID) Latest News

Dec 31, 2022

Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Dec 31, 2022

Oct 02, 2026

X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo Finance

Oct 02, 2026

Sep 29, 2026

BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne - GlobeNewswire Inc.

Sep 29, 2026

Sep 12, 2026

Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo! Finance Canada

Sep 12, 2026

Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

OVID Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus

Sep 11, 2026

H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com

Sep 11, 2026

H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com Nigeria

Sep 11, 2026

Ovid Therapeutics (NasdaqCM:OVID) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 11, 2026

Sep 09, 2026

Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus By Investing.com - Investing.com Canada

Sep 09, 2026

Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus - Investing.com

Sep 09, 2026

Sep 05, 2026

Ovid Therapeutics Stock Price Forecast. Should You Buy OVID? - StockInvest.us

Sep 05, 2026

Sep 04, 2026

September Investor Conferences: Key Catalysts For OVID, Biomea, Nuvectis & More - RTTNews

Sep 04, 2026

Sep 03, 2026

Ovid management has two September talks scheduled - Stock Titan

Sep 03, 2026

Ovid Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 03, 2026

Aug 24, 2026

Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades - Stock Titan

Aug 24, 2026

Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Yahoo Finance

Aug 24, 2026

Aug 22, 2026

Ovid (OVID) Shares: Posts a 2.19% Gain to $2.80; Range Check: the Supplied Trading Band Runs From $2.66 to $2.94 in the Latest ReadingDividend ETF - vinanet.vn

Aug 22, 2026

Aug 21, 2026

Ovid (OVID) Momentum: Finishes 2.19% Higher at $2.80 at the Close; Range View: Traders Can Monitor the $2.66-$2.94 Range in the Current UpdateDeath Cross - vinanet.vn

Aug 21, 2026

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance

Aug 21, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Adds to Ovid Therapeutics Inc (OV - GuruFocus

Aug 20, 2026

Aug 19, 2026

Ovid (OVID) Quarterly Figures: EPS Prints Above Forecast in the Latest Reading; Investor Response: The Share Price Adds 1.94% in Latest TradingProfit Inflection Point - vinanet.vn

Aug 19, 2026

Aug 18, 2026

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Aug 18, 2026

Aug 16, 2026

OVID Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 1.07%Earnings Acceleration Picks - vinanet.vn

Aug 16, 2026

Aug 15, 2026

Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen - marketbeat.com

Aug 15, 2026

Aug 14, 2026

Morgan Stanley (OVID) investor files to sell 150,000 shares valued at $420,000 - Stock Titan

Aug 14, 2026

Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake - Stock Titan

Aug 14, 2026

RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants - Stock Titan

Aug 14, 2026

Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics - Stock Titan

Aug 14, 2026

LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 14, 2026

Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Aug 14, 2026

Ovid Therapeutics (OVID) sees 4.99% beneficial stake reported by Balyasny group - Stock Titan

Aug 14, 2026

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance

Aug 14, 2026

Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada

Aug 14, 2026

Aug 13, 2026

Affinity Asset Advisors (OVID) discloses 15.1M-share Ovid stake with warrant cap - Stock Titan

Aug 13, 2026

Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Aug 13, 2026

Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings - MarketBeat

Aug 13, 2026

Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com

Aug 13, 2026

Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK

Aug 13, 2026

Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026